Abeona Therapeutics Stock Performance
ABEO Stock | USD 7.25 0.09 1.23% |
On a scale of 0 to 100, Abeona Therapeutics holds a performance score of 8. The firm shows a Beta (market volatility) of 1.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Abeona Therapeutics will likely underperform. Please check Abeona Therapeutics' potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Abeona Therapeutics' price patterns will revert.
Risk-Adjusted Performance
8 of 100
Low | High |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Abeona Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady technical and fundamental indicators, Abeona Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.23) | Five Day Return (3.07) | Year To Date Return 31.1 | Ten Year Return (98.95) | All Time Return (100.00) |
Last Split Factor 1:25 | Last Split Date 2022-07-05 |
1 | Mark Alvino Sells 7084 Shares of Abeona Therapeutics Inc Stock - MarketBeat | 01/22/2024 |
2 | Individual investors in Abeona Therapeutics Inc. are its biggest bettors, and their bets paid off as stock gained 45 percent last week | 02/12/2024 |
3 | Head to Head Comparison Abeona Therapeutics vs. Celularity | 02/16/2024 |
4 | Purchase by Joseph Vazzano of 2986 shares of Abeona Therapeutics | 02/21/2024 |
5 | Hedge funds investors have a lot riding on Abeona Therapeutics Inc. with 33 percent ownership | 02/27/2024 |
6 | Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | 03/05/2024 |
7 | Worth Venture Partners LLC Acquires 121,969 Shares of Abeona Therapeutics Inc - MarketBeat | 03/06/2024 |
8 | Schonfeld Strategic Advisors LLC Takes Position in Abeona Therapeutics Inc - Defense World | 03/12/2024 |
9 | Disposition of 703 shares by Joseph Vazzano of Abeona Therapeutics at 8.14 subject to Rule 16b-3 | 03/15/2024 |
10 | Abeona Therapeutics GAAP EPS of -2.53, revenue of 3.5M | 03/18/2024 |
11 | Abeona Therapeutics Full Year 2023 Earnings EPS Misses Expectations | 03/20/2024 |
12 | Acquisition by Edward Carr of 238000 shares of Abeona Therapeutics subject to Rule 16b-3 | 03/22/2024 |
13 | Heres Why Were Not Too Worried About Abeona Therapeutics Cash Burn Situation | 03/26/2024 |
Begin Period Cash Flow | 14.6 M |
Abeona |
Abeona Therapeutics Relative Risk vs. Return Landscape
If you would invest 553.00 in Abeona Therapeutics on December 30, 2023 and sell it today you would earn a total of 172.00 from holding Abeona Therapeutics or generate 31.1% return on investment over 90 days. Abeona Therapeutics is currently generating 0.6004% in daily expected returns and assumes 5.6329% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Abeona, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Abeona Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abeona Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abeona Therapeutics, and traders can use it to determine the average amount a Abeona Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1066
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ABEO | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
5.63 actual daily | 49 51% of assets are more volatile |
Expected Return
0.6 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Abeona Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abeona Therapeutics by adding it to a well-diversified portfolio.
Abeona Therapeutics Fundamentals Growth
Abeona Stock prices reflect investors' perceptions of the future prospects and financial health of Abeona Therapeutics, and Abeona Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abeona Stock performance.
Return On Equity | -2.61 | ||||
Return On Asset | -0.47 | ||||
Current Valuation | 153.96 M | ||||
Shares Outstanding | 27.36 M | ||||
Price To Earning | 0.11 X | ||||
Price To Book | 13.61 X | ||||
Price To Sales | 57.21 X | ||||
Revenue | 3.5 M | ||||
Gross Profit | (28 M) | ||||
EBITDA | (45 M) | ||||
Net Income | (54.19 M) | ||||
Cash Per Share | 3.38 X | ||||
Debt To Equity | 0.42 % | ||||
Current Ratio | 2.21 X | ||||
Cash Flow From Operations | (37.01 M) | ||||
Earnings Per Share | (2.53) X | ||||
Total Asset | 64 M | ||||
Retained Earnings | (749.52 M) | ||||
Current Asset | 31.95 M | ||||
About Abeona Therapeutics Performance
To evaluate Abeona Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Abeona Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Abeona Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Abeona Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Abeona's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.95) | (0.91) | |
Return On Assets | (0.85) | (0.89) | |
Return On Equity | (3.65) | (3.84) |
Things to note about Abeona Therapeutics performance evaluation
Checking the ongoing alerts about Abeona Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abeona Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Abeona Therapeutics is way too risky over 90 days horizon | |
Abeona Therapeutics appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 3.5 M. Net Loss for the year was (54.19 M) with loss before overhead, payroll, taxes, and interest of (28 M). | |
Abeona Therapeutics currently holds about 20.1 M in cash with (37.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
Abeona Therapeutics has a frail financial position based on the latest SEC disclosures | |
Roughly 60.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: Heres Why Were Not Too Worried About Abeona Therapeutics Cash Burn Situation |
- Analyzing Abeona Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abeona Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Abeona Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abeona Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abeona Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abeona Therapeutics' stock. These opinions can provide insight into Abeona Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.Note that the Abeona Therapeutics information on this page should be used as a complementary analysis to other Abeona Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Abeona Stock analysis
When running Abeona Therapeutics' price analysis, check to measure Abeona Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abeona Therapeutics is operating at the current time. Most of Abeona Therapeutics' value examination focuses on studying past and present price action to predict the probability of Abeona Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abeona Therapeutics' price. Additionally, you may evaluate how the addition of Abeona Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Abeona Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.53) | Revenue Per Share 0.164 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (2.61) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.